The first vaccine in the U.S. has been granted Emergency Use Authorization and begun distribution and inoculation among the first group of recipients: frontline healthcare providers and assisted-living residents. Questions remain, however, about Pfizer's data and long-term studies. To learn more we chatted with Pfizer's Vice President and Chief Scientific Officer for viral Vaccines, Dr. Phil Dormitzer, who leads Pfizer's research and development into viral vaccines.